The Efficacy of Lambrolizumab in Advanced Melanoma

Antoni Ribas, MD, PhD, the director of the Tumor Immunology Program Area at UCLA's Jonsson Comprehensive Cancer Center, comments on the efficacy of lambrolizumab, an anti-PD-1 antibody, in patients with advanced melanoma.

Clinical Pearls

Researchers have seen clinically meaningful activity in a substantial number of patients, Ribas says. In the trial, the overall response rate was 38% and 90% of patients experienced durable response. Ribas notes that adverse events in the trial were minimal.

• Clinically meaningful activity was observed in the trial
• The overall response rate was 38%, pooled across all doses and schedules and including both ipilimumab-naive and ipilimumab-pretreated patients
• Preliminary data suggest that lambrolizumab has significant antitumor activity and is well tolerated with manageable side effects in both ipilimumab-naive and ipilimumab-pretreated patients with melanoma

<<<

View all coverage from the 2013 ASCO Meeting